Autopsy report · NCT01723813
Peptide Vaccinations Plus GM-CT-01 in Melanoma
Cause of deathOther
“due to end of validity of peptide vaccine”
Life of this trial
- Registered 5 months after it had already started.
- Ran for about 3 years before it stopped.
- 6 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Sponsor type
- University, hospital or other
- Conditions
- Metastatic Melanoma
- Interventions
- Tumor specific peptides: MAGE-3.A1 and / or NA17.A2; Galectin-3 inhibitor: GM-CT-01 systemic injections; Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration
- Participants
- 6
- Sites
- 1
- Countries
- Belgium
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.